Healthcare Weekly: JPM Healthcare Conference 2023 – Top 5 Biotech

JPM Healthcare Conference 2023 – Top 5 Biotech

Five of the most anticipated biotech presentations take place on the first day of the 2023 J.P. Morgan Healthcare Conference. There’s no faster way to get up to speed on a name – or refresh your memory – than with a great expert call transcript. Enjoy!

APLS (Monday, 9:00am PT)

ASND (Monday, 9:00am PT)

CYTK (Monday, 9:00 am PT)

SRPT (Monday, 10:30am PT

SGEN (Monday, 3:00pm PT)

APLS (Apellis Pharmaceuticals Inc)

• Ophthalmologist Thinks Use of Pegcetacoplan Will Be ~30-40% of Patients With GA When It Gets Approved, Doctor/Medical Professional University of Pennsylvania – Ophthalmology (Current)

ASND (Ascendis Pharma)

• Former Sr. Director Sees Reservations On Potential Skytrofa Uptake, Ascendis Pharma A/S – Sr. Director (Prior)

CYTK (Cytokinetics Inc)

• Former Head of Health Economics & Outcomes Research Expects Eventual FDA Approval for Omecamtiv and Aficamten, Cytokinetics – Head of Health Economics & Outcomes Research (Prior)

SRPT (Sarepta Therapeutics Inc)

• Former Sr. Engineer Thinks SRPT Will Get FDA Approval For Duchenne Muscular Dystrophy, Sarepta Therapeutics, Senior Engineer – Gene Therapy Upstream (Prior)
• Former Sr. Director Thinks SRPT’s Duchenne Muscular Dystrophy Drug Is Effective, but Approval Timing is Crucial, Sarepta Therapeutics – Senior Director (Prior)

SGEN (Seagen Inc)

• Former EVP Thinks There Are Challenges Ahead for SGEN’s Growth and Sees Sale as the Most Appropriate Course of Action, Seattle Genetics – Executive Vice President (Prior)
• Pediatric Hematologist Oncologist Sees SGEN’s Adcetris as New Standard of Care in First-line, High-Risk Pediatric Classical Hodgkin Lymphoma, Mercy – Pediatric Hematologist Oncologist (Current)
• Hematologist Oncologist Is Very Positive on the FDA Approval of SGEN’s Adcetris for Pediatric Patients With Classical Hodgkin Lymphoma, Rutgers Medical School – Hematologist Oncologist (Current)

ABOUT THE AUTHOR

Austin Moorhead
Content Marketing for Stream by AlphaSense

Austin’s primary experience is in consulting and private equity, though he’s also a published author.

Read all posts written by Austin Moorhead